TPD & Induced Proximity Summit Leaderboard
  • Thursday, July 2, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Oligonucleotides Analytical Development & CMC Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Page 932

Lantern Pharma Announces Transaction to Evaluate BioNumerik’s Tavocept

Aug 8, 2016
Lantern Pharma has entered into an exclusive agreement to evaluate BioNumerik Pharmaceuticals' Tavocept for human therapeutic indications using Lantern’s 5-M theranostic platform.…
Read More...

DNAtrix Awarded FDA Orphan Products Development Grant for DNX-2401

Aug 5, 2016
DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced the award of a $2 million research grant from the FDA’s Office of Orphan…
Read More...

Pluristem Therapeutics Deploys Medidata’s Cloud Technology

Aug 4, 2016
Medidata announced that its cloud technology platform has been adopted by Pluristem Therapeutics. The Israeli biotech will deploy Medidata Rave to capture, manage and maximize the value…
Read More...

Allergan sells global generics business to Teva Pharmaceuticals

Aug 3, 2016
Allergan has completed the divestiture of its global generic pharmaceuticals business to Teva Pharmaceutical Industries. Allergan has received $33.4 billion in cash and 100.3 million…
Read More...

Ligand Announces Multi-Program LTP Technology Licensing Agreement with Nucorion Pharmaceuticals

Aug 1, 2016
Ligand Pharmaceuticals Incorporated announces the signing of a license agreement for three programs utilizing Ligand’s LTP (Liver Targeting Prodrug) technology with Nucorion…
Read More...

DNAtrix Receives European Medicines Agency PRIME Designation

Jul 28, 2016
DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced that the European Medicines Agency (EMA) has granted PRIority MEdicines…
Read More...

Synaffix achieves improved therapeutic index compared to both FDA-approved ADCs

Jul 22, 2016
Synaffix has completed a new set of preclinical studies that further supports the potential for its technology to enable safer and more effective targeted cancer therapeutics. The…
Read More...

DNAtrix Announces Successful Intratumoral Delivery of DNX-2401 via Alcyone’s MEMS Cannula for the…

Jul 22, 2016
DNAtrix, a clinical stage, biotechnology company developing virus-driven immunotherapies for cancer, announced the successful intratumoral administration of DNX-2401 with the Alcyone…
Read More...

PeptiDream Announces License of PDPS Technology to Genentech

Jul 21, 2016
PeptiDream has entered into a Technology License Agreement with US-based Genentech, a member of the Roche Group, to non exclusively license its Peptide Discovery Platform System (PDPS)…
Read More...

Hanmi Selects Medidata to Power Drug Development with Cloud Technology

Jul 6, 2016
Medidata announced that it has signed a multi-year enterprise deal with Hanmi Pharmaceutical, one of South Korea's leading drug makers. A Medidata customer since 2013, the …
Read More...
Previous 1 … 930 931 932 933 934 … 936 Next
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
Measuring Patient Engagement Summit Europe
Oligonucleotides Analytical Development & CMC Summit
11th CAR-TCR Summit
COPD Drug Development Summit
2nd Operationalize: Expanded Access Programs Summit West
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
TRP Supply Chain & Manufacturing Summit
Covalent Drug Discovery & Development Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
Lipid Nanoparticles Development Summit Europe
iPSC Drug Development Summit
17th World ADC San Diego
Oligonucleotides for CNS Summit
In Vivo Cell Engineering & Gene Editing Summit
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Zymeworks to Acquire Theravance Biopharma in $929 Million Deal
  • EMA Panel Backs Lilly’s Jaypirca for Chronic Lymphocytic Leukemia
  • Talawar Therapeutics Announces $285 Million Nasdaq Merger Deal
  • AstraZeneca, YMCA Launch National Cancer Education Partnership
  • Antares, Novartis Partner on Cancer Drug Discovery

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Respiratory Medicine Following ATS – What Now?

World ADC San Diego Unveils Preliminary Agenda for 17th…

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.